Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  Issue: October 2015  |  October 13, 2015

Intraoral and panoramic radiographs and cone beam computed tomography (CBCT), a form of focused CT of the jawbones, help delineate the extent of the disease.54,55 Radiographs show poorly demarcated, mottled radiolucencies, with or without sequestra, and often thickening of the lamina dura, the thin shell of bone that surrounds teeth.

Management

Prevention of MRONJ should be the goal and measures should be initiated before or shortly after starting medications that predispose patients to MRONJ.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

All patients should be seen by a dentist for a baseline examination and radiographs. This is particularly important for patients with cancer who are higher risk. Because infection is one of the predisposing factors, all dental treatment to reduce and eliminate infection should be completed as quickly as possible, such as having dental restorations placed, teeth cleaned and unrestorable teeth extracted. Even if the incidence of MRONJ is low, such as in the osteoporosis population, removing all sources of dental infection is good practice for the overall health and well-being of the patient.

At this time, anti-resorptive agent-related osteonecrosis by far outnumbers cases caused by other agents.

If the patient requires extraction of a tooth after having been on bisphosphonates for many years, this may be unavoidable because not treating sites of infection also predisposes the patient to MRONJ. There is no absolute contraindication to extraction, and this may be the most appropriate treatment for teeth that are mobile (grade III or higher) and at risk for aspiration, teeth that are in areas of ONJ as determined radiographically and when the patient has continued to have pain and infection despite multiple courses of antibiotic treatment. If the patient has had substantial exposure to bisphosphonate therapy, non-restorable teeth can receive root canal therapy, provided there is no obvious bone disease on the radiographs. Patients should then be followed routinely for regular dental check-ups and dental cleanings.Figures 4A & B: Nonsurgical sequestrectomy: (top) necrotic bone on lingual mandible; and (bottom) removal of fragment of necrotic bone by simple mobilization.

The AAOMS recommends discontinuation of oral bisphosphonates for two months prior to extractions for those patients who have taken an oral bisphosphonate for more than four years or for those patients who have taken an oral bisphosphonate for less than four years with concomitant medical therapy (corticosteroids or anti-angiogenic agents).5 This is controversial because the half-life of bisphosphonates is approximately 10 years, and this would have little effect on bone healing. In contrast, the half-life of denosumab is shorter (32 days), with a terminal half-life of 5–10 days.56

Bisphosphonate use is associated with MRONJ in both patients on cancer therapy (frequency of 1–7%) & those with osteoporosis (frequency of 0.02%).

There are some data that soft-tissue healing may be compromised by bisphosphonates, but this effect is present only for a few weeks after exposure.17 The duration and necessity of a drug holiday after patients have been on anti-resorptive therapies for osteoporosis for years have yet to be clearly elucidated.57

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

Related Articles
    BlurryMe / shutterstock.com

    The Prevention & Management of Medication-Related Osteonecrosis of the Jaw

    March 15, 2021

    Medication-related osteonecrosis of the jaw (MRONJ) is a con­dition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are admin­istered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…

    Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

    December 12, 2022

    A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

    Reading Rheum

    May 1, 2009

    Handpicked Reviews of Contemporary Literature

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences